This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Pediatric Device Consortium | |
|---|---|
| Name | Pediatric Device Consortium |
| Formation | 2009 |
| Founder | United States Food and Drug Administration |
| Purpose | Pediatric medical device development and regulatory support |
| Headquarters | Silver Spring, Maryland |
| Region served | United States |
| Parent organization | Food and Drug Administration |
Pediatric Device Consortium
The Pediatric Device Consortium was established to accelerate development, evaluation, and commercialization of medical devices for children, providing regulatory science, engineering, and clinical trial support. It connects academic centers, medical device innovators, pediatric hospitals, and regulatory experts to address market failures in pediatric device development. The Consortium operates through funded hubs, collaborates with federal agencies, and partners with industry and nonprofit stakeholders to translate prototypes into approved pediatric technologies.
The Consortium functions as a network of regional cores that provide design engineering, regulatory strategy, biostatistics, and clinical trial facilitation to advance pediatric devices from concept to market. Participating institutions include Children's Hospital of Philadelphia, Boston Children's Hospital, Stanford University, Vanderbilt University Medical Center, and University of Michigan Health System. The initiative coordinates with National Institutes of Health, Biomedical Advanced Research and Development Authority, National Science Foundation, Department of Health and Human Services, and the Centers for Medicare & Medicaid Services. Core activities emphasize pediatric-specific device design, human factors engineering, preclinical testing, and submission support for Food and Drug Administration pathways such as 510(k) and Premarket Approval.
The Consortium emerged after recognition of gaps highlighted by reports from Institute of Medicine and policy statements from American Academy of Pediatrics and stakeholders like AdvaMed. Legislative and regulatory milestones influencing its creation include the Medical Device User Fee and Modernization Act and the FDA Safety and Innovation Act. Initial pilot hubs launched following cooperative agreements with the United States Food and Drug Administration Office of Pediatric Therapeutics, building on precedents set by programs at Duke University, Johns Hopkins University, and Cincinnati Children's Hospital Medical Center. Over time, the network expanded through competitive awards administered alongside Office of Orphan Products Development and other federal research funding mechanisms.
The Consortium is organized into regional centers and specialty cores hosted by academic medical centers and research universities. Governance involves scientific advisory boards with representation from American College of Cardiology, Society for Cardiovascular Angiography and Interventions, Society for Pediatric Research, and industry councils including members of Medical Device Manufacturers Association and AdvaMed. Funding streams include cooperative agreements from the Food and Drug Administration, grants from the National Institutes of Health, philanthropic contributions from organizations such as March of Dimes and Cystic Fibrosis Foundation, and in-kind industry partnerships with companies like Medtronic, Johnson & Johnson, Boston Scientific, and Edwards Lifesciences.
Services provided across Consortium hubs include engineering prototyping, bench and animal model testing, human factors and usability studies, biostatistics and clinical trial design, quality system consultation, and regulatory submission assistance for pathways such as 510(k), De Novo, and Premarket Approval. Educational programs encompass workshops with FDA Center for Devices and Radiological Health staff, training for investigators from American Academy of Pediatrics sections, and entrepreneurship curricula linked to MassChallenge and academic technology transfer offices at Massachusetts Institute of Technology and University of California, San Francisco. The Consortium also operates device incubators, seed funding programs, and patient engagement initiatives collaborating with advocacy groups like Parent Project Muscular Dystrophy and St. Jude Children's Research Hospital.
Strategic collaborations include alliances with federal partners National Institutes of Health, Centers for Disease Control and Prevention, and the Defense Advanced Research Projects Agency for specific technology challenges. Academic partnerships span Harvard Medical School, Yale University, University of Pittsburgh Medical Center, and international collaborators such as Great Ormond Street Hospital and Royal Children's Hospital, Melbourne. Industry consortia, venture capital firms, and nonprofit funders participate in public–private partnerships alongside regulatory liaisons from Food and Drug Administration programs and professional societies like American Academy of Orthopaedic Surgeons and American Heart Association.
The Consortium has supported translation of pediatric technologies including pediatric ventricular assist devices, neonatal respiratory support systems, pediatric orthopedic implants, and neurostimulation tools, contributing to submissions to the Food and Drug Administration and CE marking processes administered under European Medicines Agency frameworks. Outcomes include increased numbers of pediatric-specific studies registered on ClinicalTrials.gov, enhanced investigator-initiated device trials at centers like Texas Children's Hospital, and strengthened pathways for small businesses utilizing the Small Business Innovation Research and Small Business Technology Transfer programs. The initiative has informed guidance documents and consensus statements from organizations such as American Academy of Pediatrics and Society of Pediatric Nurses.
Persistent challenges include small patient populations, heterogeneous pediatric anatomies, reimbursement hurdles involving Centers for Medicare & Medicaid Services, and high development costs that deter traditional investors. Future directions emphasize scalable manufacturing, advanced simulation with partners like Siemens Healthineers and GE Healthcare, integration of pediatric-specific digital health and artificial intelligence under frameworks discussed by National Academy of Medicine, and expansion of international regulatory harmonization with regulators such as European Medicines Agency and Health Canada. The Consortium aims to leverage novel financing models, broaden patient advocacy engagement with groups like Save the Children, and strengthen translational pipelines through closer ties to innovation ecosystems at Stanford University and University of California, Berkeley.
Category:Medical and health organizations